BCW member Regeneron has reached a significant milestone in rare-disease treatment with U.S. Food and Drug Administration approval of Pasatru™ (garetosmab-grts), a new therapy for adults living with fibrodysplasia ossificans progressiva (FOP). The treatment is the first FDA-approved therapy shown in a placebo-controlled trial to reduce both the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with the ultra-rare condition. FOP is a progressive genetic disorder in which abnormal bone forms within muscles, tendons, ligaments and other connective tissues. Over time, this rogue bone growth can severely restrict movement and make everyday activities such as walking, eating, […]